Hepatocellular Carcinomas in Patients With Metabolic Syndrome Often Develop Without Significant Liver Fibrosis: A Pathological Analysis

被引:418
作者
Paradis, Valerie [1 ]
Zalinski, Stephane [2 ,3 ]
Chelbi, Emna
Guedj, Nathalie [1 ]
Degos, Francoise
Vilgrain, Valerie
Bedossa, Pierre [1 ]
Belghiti, Jacques [2 ,3 ]
机构
[1] Hop Beaujon, INSERM, Unite 773, F-92100 Clichy, France
[2] Hop Beaujon, AP HP, Serv Chirurg Hepatobiliaire, F-92100 Clichy, France
[3] Inst Natl Sante & Rech Med, Unite 773, Paris, France
关键词
NONALCOHOLIC STEATOHEPATITIS; CRYPTOGENIC CIRRHOSIS; NATURAL-HISTORY; DIABETES-MELLITUS; CANCER-RISK; OBESITY; DISEASE; COHORT;
D O I
10.1002/hep.22734
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Metabolic syndrome (MS) is a newly identified risk factor in chronic liver disease (CLD) and hepatocellular carcinoma (HCC). The aim of this study was to analyze the pathological characteristics of HCC and nontumoral liver in patients with MS as the only risk factor for liver disease in comparison with those that developed in die course of other CLDs in order to provide further insight into the physiopathology of HCC associated with MS. HCC patients with features of MS as the only risk factor for liver diseases (MS group, n = 31) were compared to HCC patients with overt causes of CLD (CLD group, n = 81) or without causes of CLD (cryptogenic group, n = 16) who underwent surgical resection during the same period of time. Among the patients of the MS group, there were 30 males and I female. In comparison with the patients with HCC of the CLD group, the patients with MS were older (mean age: 67 +/- 7 versus 59 +/- 14 years, P < 0.01), and the background liver was significantly more often free of significant fibrosis (170-172: 65% in the MS group versus 26% in the CLD group, P < 0.001). In addition, HCCs associated with MS were more often well differentiated (65% versus 28%, P < 0.001). Five HCCs, all from the MS group, developed on a preexisting liver cell adenoma, with three of them showing typical histological features of telangiectatic adenoma. Conclusion: This study shows that HCCs in patients with features of MS as the only risk factor for liver disease have distinct morphological characteristics and mainly occur in the absence of significant fibrosis in the background liver. In addition, some of them arise through malignant transformation of a preexisting liver cell adenoma. (HEPATOLOGY 2009,49:851-859.)
引用
收藏
页码:851 / 859
页数:9
相关论文
共 40 条
[1]   The natural history of nonalcoholic fatty liver disease: A population-based cohort study [J].
Adams, LA ;
Lymp, JF ;
St Sauver, J ;
Sanderson, SO ;
Lindor, KD ;
Feldstein, A ;
Angulo, P .
GASTROENTEROLOGY, 2005, 129 (01) :113-121
[2]   Nonalcoholic fatty liver disease [J].
Brunt, Elizabeth M. ;
Wong, Vincent W. -S. ;
Nobili, Valerio ;
Day, Christopher P. ;
Sookoian, Silvia ;
Maher, Jacquelyn J. ;
Bugianesi, Elisabetta ;
Sirlin, Claude B. ;
Neuschwander-Tetri, BrentA. ;
Rinella, Mary E. .
NATURE REVIEWS DISEASE PRIMERS, 2015, 1
[3]   An algorithm for the grading of activity in chronic hepatitis C [J].
Bedossa, P ;
Poynard, T .
HEPATOLOGY, 1996, 24 (02) :289-293
[4]   Primary liver cancer:: Worldwide incidence and trends [J].
Bosch, FX ;
Ribes, J ;
Díaz, M ;
Cléries, R .
GASTROENTEROLOGY, 2004, 127 (05) :S5-S16
[5]   Expanding the natural history from cryptogenic cirrhosis to of nonalcoholic steatohepatitis: Hepatocellular carcinoma [J].
Bugianesi, E ;
Leone, N ;
Vanni, E ;
Marchesini, G ;
Brunello, F ;
Carucci, P ;
Musso, A ;
De Paolis, P ;
Capussotti, L ;
Salizzoni, M ;
Rizzetto, M .
GASTROENTEROLOGY, 2002, 123 (01) :134-140
[6]   Obesity and hepatocellular carcinoma [J].
Caldwell, SH ;
Crespo, DM ;
Kang, HS ;
Al-Osaimi, AMS .
GASTROENTEROLOGY, 2004, 127 (05) :S97-S103
[7]   Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease [J].
Caldwell, SH ;
Oelsner, DH ;
Iezzoni, JC ;
Hespenheide, EE ;
Battle, EH ;
Driscoll, CJ .
HEPATOLOGY, 1999, 29 (03) :664-669
[8]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[9]   Nonalcoholic steatohepatitis [J].
Diehl, AM .
SEMINARS IN LIVER DISEASE, 1999, 19 (02) :221-229
[10]   The metabolic syndrome [J].
Eckel, RH ;
Grundy, SM ;
Zimmet, PZ .
LANCET, 2005, 365 (9468) :1415-1428